ID   BT359
AC   CVCL_WW63
SY   BT 359; CPDM_1300X
DR   PharmacoDB; BT359_139_2019
DR   Wikidata; Q93432634
RX   PubMed=34610309;
WW   Provider; CPDM; CPDM_1300X; https://docs.google.com/spreadsheets/d/1sxAPF3p6xK2h01zaiQ1ExCWwzhxeZ-oDLN3s3LeJq98/edit?usp=sharing
CC   Part of: Center for Patient Derived Models (CPDM) at Dana-Farber Cancer Institute cell line panel.
CC   Characteristics: Low-passage-number culture.
CC   Characteristics: Can grow as a neurosphere (PubMed=34610309).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing; Low read coverage.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Brain, left temporal cortex; UBERON=UBERON_0016538.
DI   NCIt; C39750; Glioblastoma, IDH-wildtype
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 10-04-25; Version: 6
//
RX   PubMed=34610309; DOI=10.1016/j.celrep.2021.109788;
RA   Stockslager, Max A.
RA   Malinowski, Seth
RA   Touat, Mehdi
RA   Yoon, Jennifer C.
RA   Geduldig, Jack
RA   Mirza, Mahnoor
RA   Kim, Annette Sunhi
RA   Wen, Patrick Yung-Chih
RA   Chow, Kin-Hoe
RA   Ligon, Keith Lloyd
RA   Manalis, Scott R.
RT   "Functional drug susceptibility testing using single-cell mass
RT   predicts treatment outcome in patient-derived cancer neurosphere
RT   models.";
RL   Cell Rep. 37:109788.1-109788.12(2021).
//